Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide

Abstract

Study Objective To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ). Design Randomized multicenter clinical trial. Patients A total of 735 white or African-American men and women with uncomplicated hypertension. Measurements and Main Results Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively. Conclusion Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.

Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients

“…The analysis was adjusted for age, sex, and baselines glucose because these were associated with the change in glucose post chlorthalidone treatment in our study. Also, studies have shown baselines glucose to be a significant predictor of thiazide‐associated glucose change . Furthermore, even though we did not find any population substructure in our cohort, principal components 1 and 2 were included in the model to account for ancestry.…”

Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study

“…The cause of the increase in uric acid can likely be explained by the addition of hydrochlorothiazide, because elevated uric acid is a common side effect of diuretics. 4 These adverse events were manageable and did not pose a health risk.…”

Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach

“…We have previously reported that participants with lower baseline glucose measures exhibited the largest variation in glucose after antihypertensive drug exposure (Moore et al 2014). Therefore, participants with impaired fasting glucose (IFG), defined as baseline fasting glucose levels ≥100 mg/dL, were excluded from our metabolomics analysis in order to observe the maximum effect of antihypertensive treatment on glucose level.…”